Plain-English translation of NCT07296315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called MH002 to see if it works and is safe for people with ulcerative colitis—a bowel disease that causes inflammation and sores in the gut. MH002 is made of live bacteria designed to help restore your gut's normal function. A smaller earlier study in 45 patients showed promising results, and now researchers want to test two different doses in about 200 patients to confirm these benefits.
Many people with ulcerative colitis don't get enough relief from standard medications like 5-aminosalicylic acid (the first-line treatment). This medication offers a new approach using beneficial bacteria, which could provide another option for people who aren't responding well to current treatments.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of three treatments: a low dose of MH002, a high dose of MH002, or a placebo (inactive substance). Neither you nor the study team would know which treatment you're receiving. You would take the medication and attend study visits where researchers check your symptoms, perform blood tests, and use colonoscopy to see how your colon is healing. The study will track both how well the medication works and any side effects over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States